MB07133 gets orphan drug status

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 16 No 11
Volume 16
Issue 11

MB07133 gets orphan drug status

SAN DIEGO—Metabasis Therapeutics' MB07133 has received orphan drug status from FDA for the treatment of hepatocellular carcinoma. MB07133 is a novel HepDirect prodrug of cytarabine monophosphate designed to produce the oncolytically active form, cytarabine triphosphate, in the liver tumor where it acts to inhibit cell proliferation and induce apoptosis.

Articles in this issue
MT103, BiTE antibody, enters phase II testing for ALL
Sides dig in as ESA policy debate heats up
Ixempra gets ok for resistant breast cancer
ASCO adds Oncotype DX to marker guideline
Dr. Norton hopes to weed 'molecular' tumor garden
Accelerated approval for Tasigna
Oxidative stress inducer ups survival in advanced melanoma
FDA removes partial hold on Telcyta clinical development
Should all HER2+ pts receive adjuvant trastuzumab?
R-CHOP is standard of care for advanced DLBCL patients
FDA oks Velcade for patients with renal dysfunction
Phase II trials planned for oral methylnaltrexone for chronic pain
GSK and Synta announce STA-4783 collaboration
2007: A tumultuous year for erythropoietic-stimulating agents
MB07133 gets orphan drug status
Recent Videos
Select comorbidities, ECOG status, and the receipt of radiation were among the differences between a real-world cohort and the RUBY trial population.
Related Content
Phase 2 data may support atezolizumab plus chemotherapy as a treatment option in advanced or recurrent thymic carcinoma.

Atezolizumab/Chemotherapy May Show Meaningful Activity in Thymic Carcinoma

Russ Conroy
March 21st 2025
Article

Phase 2 data may support atezolizumab plus chemotherapy as a treatment option in advanced or recurrent thymic carcinoma.

Low grade serous ovarian cancer, a rare epithelial ovarian cancer subtype, requires differentiated treatment from its high-grade counterpart.

Redefining the Treatment Paradigm in Low Grade Serous Ovarian Cancer

Kathleen N. Moore, MD, MS
March 17th 2025
Podcast

Low grade serous ovarian cancer, a rare epithelial ovarian cancer subtype, requires differentiated treatment from its high-grade counterpart.

FDA Approves PET Imaging Agent for Prostate Cancer

FDA Approves PET Imaging Agent for Prostate Cancer

Ariana Pelosci
March 21st 2025
Article

The new drug application for TLX007-CDx has been approved by the FDA for patients with prostate cancer.

Oncologists Reflect on Pandemic's Lasting Impact on Cancer Care

Oncologists Reflect on Pandemic's Lasting Impact on Cancer Care

Aditya Bardia, MD, MPH;Ritu Salani, MD;Scarlett Lin Gomez, PhD;Marwan G. Fakih, MD;Elizabeth Ren Zhang-Velten, MD, PhD;Frances Chow, MD;James B. Yu, MD, MHS, FASTRO
March 10th 2025
Podcast

Hear from leading cancer experts about the lasting impact the COVID-19 pandemic has left on clinical practice.

Durvalumab Does Not Surpass Cetuximab in Head and Neck Cancer

Durvalumab Does Not Surpass Cetuximab in Head and Neck Cancer

Ariana Pelosci
March 20th 2025
Article

Christina Henson, MD, discusses recent phase 3 trial results comparing durvalumab to cetuximab in head and neck cancer, and why the trial was stopped early.

Timely guideline-concordant care may mitigate racial and ethnic disparities in overall survival among patients with inflammatory breast cancer.

Data Show Guideline-Concordant Care Gaps in Inflammatory Breast Cancer

Russ Conroy
March 20th 2025
Article

Timely guideline-concordant care may mitigate racial and ethnic disparities in overall survival among patients with inflammatory breast cancer.